Hemophagocytic Lymphohistiocytosis in 2 Patients with Multiple Sclerosis Treated With Alemtuzumab
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Alemtuzumab is a highly effective treatment of relapsing-remitting multiple sclerosis (RRMS) with a complex safety profile, including secondary autoimmunity in 40% of patients [1]. We report two cases of hemophagocytic lymphohistiocytosis (HLH) in patients after alemtuzumab treatment of RRMS. This hyperinflammatory syndrome consists of fever, lymphadenopathy, pancytopenia, liver abnormalities, hyperferritinemia, raised soluble interleukin 2 (IL2) receptor and hemophagocytosis; it may be secondary to malignancies, autoimmune diseases, or infections [2]. Table 1 summarizes the diagnostic criteria for secondary HLH.
Description
Keywords
Journal Title
Neurology
Conference Name
Journal ISSN
Volume Title
90
Publisher
Wolters Kluwer Health
Publisher DOI
Sponsorship
Wellcome Trust (105924/Z/14/Z)
Wellcome Trust (105924/Z/14/A)
Wellcome Trust (105924/Z/14/Z)
Wellcome Trust (105924/Z/14/A)
Wellcome Trust (105924/Z/14/Z)